小剂量他达拉非治疗Ⅱ型糖尿病勃起功能障碍

摘要

Objective To evaluate clinical efficacy and safety of tadalafil in the treatment of type II diabetes mellitus Erectile dysfunction(DMED). Methods Based on the strategy of open randomized controlled clinical study, a total of 68 patients with DMED, were randomly divided into the tadalafil treatment group and the control group of proprietary Chinese medicines. IIEF and QoL score of patients before treatment were recorded as the baseline level, and there is no difference in two groups. Patients in the treatment group were given 10mg tadalafil orally every other day for eight weeks, and the patients in the control group given oral proprietary Chinese medicines for 8weeks. Once treatment finished, the IIEF and QoL score of patients were recorded again. Results The tadalafil group has one case off. After 8 weeks treatment, IIEF scores of 5 cases in the tadalafil treatment group and 3 cases in Chinese medicine group were 2 points higher than the baseline;IIEF scores of 18 cases in the tadalafil treatment group and 10 cases in Chinese medicine group were 5 points higher than the baseline;IIEF scores of 10 cases in the tadalafil treatment group and 20 cases in Chinese medicine group were 2 points Less than the baseline Total clinical efficiency of the tadalafil group and Chinese medicine group were 69.70% (23/33) and 35.29% (12/34) respectively.There was a significant difference (P<0.05) between the two groups. Conclusion Tadalafil showed more effective in the treatment of type II diabetes ED and well toleration for patients%　　目的探讨他达拉非治疗Ⅱ型糖尿病勃起功能障碍(DMED)的临床疗效及安全性.方法采用开放性随机对照临床研究,共68例DMED,随机分成他达拉非组和中成药复方玄驹胶囊对照组(复方玄驹组).治疗前记录两组IIEF及QoL评分作为基线水平.治疗方案：他达拉非组给予10mg,隔天口服,共8周；对照组口服中成药复方玄驹胶囊,8周后再次进行IIEF及QoL评分.比较治疗前后两组患者的变化.结果他达拉非组脱落1例.服药后他达拉非组和复方玄驹组IIEF评分：积分较基线提高≥2分别为5例和3例；≥5分为18例和10例；<2分为10例和20例；临床总有效率他达拉非组和复方玄驹组分别为69.70%(23/33),35.29%(12/34)；两组之间有明显差异(P<0.05).结论他达拉非对Ⅱ型糖尿病ED的治疗较中成药更有效,且耐受性良好.